SPP1 and myelofibrosis: Since Ulixertinib should be administered twice daily [38, 39] by oral gavage -that is an invasive procedure unsustainable in the long term- we selected the Romiplostim-treated mouse model to assess in vivo the efficacy of Ulixertinib in reducing OPN production and counteract the development of myelofibrosis.